Health Sciences Authority — Singapore Post-Registration Actions (HSA-SG)

Health Sciences Authority — Singapore Post-Registration Actions is the official source of medicine shortage information for Singapore (Asia-Pacific). Mederti checks its register daily and links every notice back to the original publication.

Official register

www.hsa.gov.sg

Country

Singapore

Notices tracked by Mederti

321

Last checked

22 May 2026

Latest notices from HSA-SG

• Estradiol — anticipated, medium, since 2 Jun 2026 (source)
• Tramadol-Hydrochloride — anticipated, medium, since 30 Mar 2026 (source)
• Micafungin Sodium — anticipated, medium, since 13 Feb 2026 (source)
• Warfarin Sodium — anticipated, medium, since 3 Feb 2026 (source)
• Galantamine-Hydrobromide — anticipated, medium, since 2 Feb 2026 (source)
• Nicotine Polacrilex — anticipated, medium, since 30 Jan 2026 (source)
• Thymosin Alpha 1(1.6 Mg/Vial) — active, medium, since 31 Dec 2025 (source)
• Mometasone Furoate — active, medium, since 31 Dec 2025 (source)
• Aztreonam(1 G/Vial) — active, medium, since 30 Dec 2025 (source)
• Cis(Z)-Flupenthixol Decanoate(20 Mg/Ml),Eptinezumab(100 Mg/Ml),Escitalopram(10 Mg),Escitalopram(15 Mg),Escitalopram(20 Mg),Escitalopram(5 Mg),Escitalopram Oxalate 12.77Mg Eqv Escitalopram(10Mg),Flupentixol Dihydrochloride Eqv Flupentixol(0.5 Mg),Memantine Hcl(10 Mg),Melitracen Hydrochloride Eqv Melitracen(10 Mg),Rasagiline Mesylate 1.56Mg Equivalent Rasagiline(1 Mg),Vortioxetine (D,L)-Lactate Eqv Vortioxetine(20 Mg/Ml),Vortioxetine (As Hydrobromide 12.710Mg)(10.00Mg),Vortioxetine (As Hydrobromide 25.420Mg)(20.00Mg),Vortioxetine (As Hydrobromide 6.355 Mg)(5.00Mg),Vortioxetine Hydrobromide Eqv Vortioxetine(10 Mg),Vortioxetine Hydrobromide Eqv Vortioxetine(20 Mg),Vortioxetine Hydrobromide Eqv Vortioxetine(5 Mg),Zuclopenthixol Decanoate(200 Mg/Ml) — active, medium, since 8 Dec 2025 (source)
• Aripiprazole-Monohydrate — active, medium, since 1 Dec 2025 (source)
• Diclofenac-Sodium — active, medium, since 25 Nov 2025 (source)
• (Powder) Trastuzumab(440 Mg/Vial),Adalimumab(40 Mg/0.8Ml),Bevacizumab(25 Mg/Ml),Etanercept(25.0 Mg/0.5Ml),Etanercept(50.0 Mg/Ml) — active, medium, since 15 Oct 2025 (source)
• Mogamulizumab(20 Mg/5Ml) — active, medium, since 15 Oct 2025 (source)
• Insulin glargine — active, medium, since 10 Oct 2025 (source)

Mederti is not affiliated with or endorsed by Health Sciences Authority — Singapore Post-Registration Actions. All notices remain the property of their publisher and are linked to the original source.